Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the Journal of the American Medical Association
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced the publication of results from the Phase 3 CLEAR Wisdom trial in the Journal of the American Medical Association (JAMA).1 Bempedoic acid is currently undergoing review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA).
CLEAR Wisdom, a Phase 3, double-blind, randomised trial, evaluated the efficacy, long-term safety and tolerability of bempedoic acid 180 mg versus placebo in 779 patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolaemia (HeFH) inadequately controlled with current lipid-modifying therapies, added on to maximally-tolerated statin therapy, which may mean no statin at all.1
The JAMA publication includes results for the primary efficacy endpoint of low-density lipoprotein cholesterol (LDL-C) lowering at 12 weeks and key secondary endpoints of safety and tolerability over 52 weeks. The publication reports that bempedoic acid:1
- significantly lowered LDL-C by 17% on background maximally-tolerated statin therapy at 12 weeks, with nearly all patients (85%, 444/522 ) on moderate- or high-intensity statins, and the effect was durable through 52 weeks;
- significantly lowered high-sensitivity C-reactive protein (hsCRP), an important marker of the underlying inflammation associated with cardiovascular disease, by 19%, and the effect was durable through 52 weeks;
- showed no worsening of haemoglobin A1c (HbA1c) (- 0.21% vs. placebo) in patients with diabetes at 12 weeks;
- showed overall adverse event rates comparable with placebo (bempedoic acid 70% 366/522 vs. placebo 71% 182/257) at 52 weeks, and the proportion of patients with reported serious adverse events was similar compared with placebo (bempedoic acid 20% 106/522 vs. placebo 19% 48/257) at 52 weeks;
- showed adjudicated three-component major adverse cardiac event rates of 2.7% (14/522) with bempedoic acid and 4.7% (12/257) with placebo.
“The CLEAR Wisdom trial demonstrated that bempedoic acid provided additional LDL-C lowering in patients on background maximally-tolerated statin therapy and had an overall adverse event profile that was comparable to placebo,” said Anne C. Goldberg MD, FACP, FAHA, FNLA, Professor of Medicine, Division of Endocrinology, Metabolism and Lipid Research at Washington University, St. Louis and lead study author. “These results are consistent with the results reported from the largest long-term Phase 3 study of bempedoic acid, Study 1 or CLEAR Harmony, which were published earlier this year in the New England Journal of Medicine. Results across the Phase 3 development programme show that bempedoic acid has the potential to be a treatment option for high-risk patients who require additional LDL-C lowering.”
“We believe that bempedoic acid will address an important unmet need for patients who require additional LDL-C lowering and are not reaching their goals with existing oral lipid lowering therapies,” said Wolfgang Zierhut, MD, Head of Antithrombotic and Cardiovascular Medical Affairs Department at Daiichi Sankyo Europe. “Many patients remain at high risk of a cardiovascular event and need additional treatment options to achieve LDL-C goals. This is even more pertinent given that the latest guidelines suggest even lower LDL-C goals to provide optimal protection.”
- ENDS -
Design of Global Pivotal Phase 3 Study 2 (1002-047, also known as CLEAR Wisdom)
The 52-week, global, pivotal Phase 3 randomised, double-blind, placebo-controlled, multi-centre study evaluated the efficacy and safety of bempedoic acid 180 mg/day versus placebo. The study was conducted at 86 sites in North America and Europe. A total of 779 patients were randomised 2:1 to receive bempedoic acid or placebo. The primary efficacy objective was to assess the 12-week LDL-C lowering efficacy of bempedoic acid versus placebo. Secondary objectives included evaluating the safety and tolerability of bempedoic acid versus placebo, the 24-week and 52-week LDL-C lowering efficacy of bempedoic acid versus placebo, and bempedoic acid’s effects on other risk markers after 12 weeks of treatment, including hsCRP and HbA1c, versus placebo.
With a targeted mechanism of action, bempedoic acid is an oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver and thereby lowers circulating LDL-C levels.2,3 It is intended for patients with hypercholesterolaemia and/or at high risk of atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering despite maximally-tolerated statin therapy.
Bempedoic acid has a unique, innovative mode of action, which is complimentary to other lipid-lowering therapies, such as statins.4 Due to its liver-specific mode of action, bempedoic acid has a reduced potential to induce the muscle-related side-effects commonly associated with statin therapy and provide additional LDL-C lowering on top of statin monotherapy in clinical trials.3
Bempedoic acid (180 mg) and the bempedoic acid / ezetimibe fixed dose combination tablet (180 mg/10 mg) are currently under review by the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use and the U.S. Food and Drug Administration for LDL-C lowering in patients who are not yet at their target LDL-C level. Daiichi Sankyo Europe licensed exclusive commercialisation rights to these products in the European Economic Area and Switzerland from Esperion. Approval decisions are expected during the first half of 2020.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centred around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
1 Goldberg AC, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780-1788. doi:10.1001/jama.2019.16585.
2 Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022–32.
3 Ballantyne CM, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis.2018;277:195–203.
4 Laufs U, et al. Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662.
Lydia Worms (Europe)
Daiichi Sankyo Europe GmbH
Communications & Product PR Europe
+49 (89) 7808751
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi Private Bank Issues Outlook 2020: Global Growth Can Endure Over the Coming Year5.12.2019 21:30:00 EET | Press release
Citi Private Bank today released its Outlook report for 2020, titled, “Staying Positive in a Negative (Yielding) World.” The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year, and highlights important multi-year investment themes for client portfolios. The report highlights Citi Private Bank’s view that global economic growth can endure through 2020 given expectations that corporate earnings will continue to grow at a solid pace; global equities may continue to rise higher; and with global fixed income yields at record lows, they anticipate the sector will continue to struggle in 2020. “The year ahead promises to be an eventful year for investors,” said David Bailin, Chief Investment Officer, Citi Private Bank. “Our Outlook 2020 cuts through the noise and focuses on what really matters for our clients’ wealth and provides sector recommendations to potentially enhance total return profiles.” He continued, “We believe gl
Kanguru Leaps Over The Competition With A New OS Agnostic Encrypted Fingerprint Access Flash Drive5.12.2019 19:31:00 EET | Press release
Kanguru is proud to announce the launch of the world’s first OS Agnostic, Fingerprint Access Hardware Encrypted Flash Drive with remote management capability. This new biometric fingerprint access flash drive supplants the bulky pinpads and fussy combo keypads of leading encrypted devices, making it much more convenient and easy to use. With just a tap of the finger, the new Kanguru Defender Bio-Elite30™ Fingerprint Hardware Encrypted Flash Drive provides quick access to encrypted files. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005662/en/ The New Kanguru Defender Bio-Elite30 Fingerprint Hardware Encrypted Flash Drive is OS Agnostic, remotely manageable, and provides best-in-class encryption with easy fingerprint access! (Photo: Business Wire) Being OS Agnostic, the Defender Bio-Elite30 can be used on virtually any machine, from Windows and MacOS, to medical equipment, smart TVs and even ATMs for making bank machi
Sensor Electronic Technology Obtains Permanent Injunction Against U.S. UV LED Companies5.12.2019 17:00:00 EET | Press release
Sensor Electronic Technology, Inc. (“SETi”), a leading global innovator of deep UV LED products and technology, announced that it successfully obtained a permanent injunction in a patent infringement lawsuit against Bolb, Inc. (“Bolb”), and Quantum Egg, Inc. (“Q-Egg”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005031/en/ The history of UV LED business (Graphic: Business Wire) The California Northern District federal court issued a permanent injunction against the sales of an accused UV LED sterilizer device, as well as any mere colorable variations, according to the parties’ stipulation. The Court will therefore prohibit the sale of similar products if they prove to be mere colorable variations of the accused products. The asserted patents in this litigation cover fundamental UV LED technology, encompassing UV LED sterilizer structures and drivers, chip fabrication, and epitaxial layer growth. Bolb is a UV LED com
SHRM--Society for Human Resource Management and Prometric Renew Long-Term Partnership with Multi-year Agreement5.12.2019 17:00:00 EET | Press release
Following a comprehensive procurement process, we’re excited to announce that SHRM--Society for Human Resource Management®, the voice of all things work, has selected Prometric® as its strategic testing partner. Under the renewal, Prometric will assist in the delivery of the SHRM Certified Professional (SHRM-CP®) and SHRM Senior Certified Professional (SHRM-SCP®) exam programs—the global certification standard for the HR profession. This agreement extends the partnership between the organizations that started in 2010. Since inception of the certification program in 2014, Prometric has partnered with SHRM to deliver more than 75,000 exams globally with over 90% growth since the first administration. With businesses increasingly recognizing that effective people management is a strategic imperative, leaders now expect HR professionals to also demonstrate the behavioral competencies required to effectively apply knowledge in the modern workplace. By incorporating key HR competencies and k
Sartorius Acquires a Majority Stake in Cell Culture Media Specialist Biological Industries5.12.2019 16:19:00 EET | Press release
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, signed an agreement to acquire a majority stake in the Israeli cell culture media developer and manufacturer Biological Industries. For approximately €45 million in cash, Sartorius is acquiring just over 50% of the shares of the company from its owners, Kibbutz Beit Haemek and private equity fund Fortissimo Capital. An option to acquire a further 20% of the shares within three years was also agreed. The transaction is subject to customary closing conditions and expected to be finalized by mid-December. “By acquiring a majority stake in Biological Industries, we are significantly expanding our cell culture media offering and complementing our product portfolio for customers in the dynamically growing advanced therapies market,” commented Joachim Kreuzburg, CEO of the Sartorius Group. Biological Industries focuses on cell culture media, particularly for cell and gene therapy, regenerat
PW Power Systems Delivers Brighter Holidays for Puerto Rico5.12.2019 16:06:00 EET | Press release
PW Power Systems (PWPS), the leading provider of aero-derivative power generation energy solutions, announces that PREPA (Puerto Rico Electric Power Authority) has three, PWPS FT8® MOBILEPAC® gas turbines ready for operation. The 30-megawatt mobile gas turbine units are now available for emergency power, as well as for grid security in support of Puerto Rico’s environmental sustainability plan. PWPS supported ARG Precision Corporation, which completed the turnkey installation of the FT8 MOBILEPAC dual-fuel capacity gas turbines at the Palo Seco Power Plant in Toa Baja. Puerto Rico Governor Wanda Vazquez said, “The three generators provide the opportunity for fast response in the event of an emergency or situation where we lose energy in the metropolitan area. In eight to ten minutes we can energize the system and provide electricity to about 40,000 customers. Critical services such as hospitals in the metropolitan area will also have that security.” “The three mega-generators can meet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom